BioTuesdays

Tag - Cellectis

BTIG starts Cellectis at buy; PT $37

BTIG launched coverage of Cellectis SA (NASDAQ:CLLS; Euronext Growth:ALCLS) with a “buy” rating and $37 price target. The stock closed at $13.86 on Aug. 8. “Despite the initial positive reaction from investors to...